Hyperkalemia Drug May Help CKD Patients Stay on Spironolactone for Resistant Hypertension
It is challenging for CKD patients to stay on spironolactone therapy because it can increase the risk of hyperkalemia, according to researchers.
Hyperkalemia
Potassium Binders Linked With Fewer Emergency Department Visits
Prescription patterns suggest patiromer is used more often for chronic treatment of hyperkalemia and polystyrene sulfonate for episodic treatment.
Low Hypokalemia Rates Observed With Short-Term Patiromer Use
In a study of hemodialysis patients, only 0.6%, 0.5%, and 0.9% hypokalemia events occurred at 1, 2, and 3 months after initiating patiromer treatment.
Patiromer and ZS-9 Risk-Benefit Profile Explored
In 3 studies, patiromer reduced serum potassium by 0.65 to 1.01 meq/L at 4 weeks.
Potassium Abnormalities Linked With Death in Heart Failure
Serum potassium concentrations outside the normal range were associated with elevated mortality risk in patients with heart failure.
Potassium Additives a Concern for Hyperkalemia Patients
Hyperkalemia management is hindered by the shortage of information about potassium additives in foods, according to the author of new review.
Hyperkalemia Ups In-Hospital Mortality in Cardiac Patients
Hyperkalemia vs normokalemia at admission to a cardiac intensive care unit was associated with 44% increased odds of in-hospital mortality, independent of illness severity and renal function.
Hyperkalemia Less Likely in PKD Patients
In a study, the risk for hyperkalemia was 5 times higher with diabetic nephropathy and twice as high with glomerulonephritis than with PKD.
Hyperkalemia Events Common With RAAS Inhibitor Use in CKD
Almost half of incident hyperkalemia events are followed by changes in RAAS inhibitor therapy.
Spironolactone Has No Effect on LVM in Hemodialysis Patients
Patients treated with the mineralocorticoid receptor antagonist had a higher frequency of moderate hyperkalemia compared with placebo recipients.
Next post in Hemodialysis
